| Document |
Document Title |
|
WO/2024/086190A1 |
The disclosure relates to chimeric antigen receptor (CAR) specific to CD 19, vectors encoding the same, and recombinant T cells comprising the CD 19 CAR. The disclosure also includes methods of administering a genetically modified T cell...
|
|
WO/2024/086521A1 |
The present disclosure relates to methods for inducing rejuvenation in a population of glial progenitor cells and methods for treating a subject having a glial cell-related disorder. Methods include administering, to the population of ad...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/082025A1 |
The present disclosure relates generally to T cells that are modified to enhance the efficiency of adoptive cell therapy (ACT) by enhancing T cell function (e.g., CAR-T cell effector function), without affecting persistence. The present ...
|
|
WO/2024/086695A2 |
Described herein are mouse models of porphyrias, including mouse models of X- linked protoporphyria and erythropoietic protoporphyria (EPP). Immortalized human CD34+ blood cell lines expressing shRNAs targeting a human Ferrochelatase (FE...
|
|
WO/2024/082269A1 |
Provided are an application of a bispecific antibody in immune cell therapy, and a method for improving immune cell killing activity.
|
|
WO/2024/084932A1 |
[Problem] To provide a new carrier peptide fragment having cell membrane permeability. [Solution] The carrier peptide fragment disclosed herein is introduced into at least the cytoplasm of a eukaryotic cell from outside the cell and comp...
|
|
WO/2024/085261A1 |
Provided are: a novel microparticle that includes miRNA for controlling the production of nitric oxide and that is an agent for promoting the production of nitric oxide, said microparticle being capable of controlling the expression of a...
|
|
WO/2024/085252A1 |
The purpose of the present invention is to provide a novel method of preparing a cell that has undergone blastogenesis. A system (100) for preparing a cell that has undergone blastogenesis comprises an irradiation means (1, 21) which irr...
|
|
WO/2024/086191A2 |
The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD 19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL...
|
|
WO/2024/085165A1 |
The present disclosure provides a cell culture medium for culturing fish cells, a culture method for fish cells, and an oral vaccine for fish. In the present disclosure, the cell culture medium for culturing fish cells preferably contain...
|
|
WO/2024/082178A1 |
Provided is a chimeric antigen receptor, comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain targets CD19, and the second antigen-binding domain targets CD22. Also provi...
|
|
WO/2024/086796A1 |
The present disclosure is generally directed to methods of using antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A,...
|
|
WO/2024/085898A1 |
The present disclosure relates to systems, apparatuses, and methods for preparing cell-based meat products (i.e., comestible meat products). In particular, a pipe-based bioreactor is disclosed having one or more substrates disposed there...
|
|
WO/2024/083135A1 |
The disclosure provides IscB polypeptides for various applications, e.g., double-strand cleavage, base editing, prime editing.
|
|
WO/2024/083213A1 |
The present invention relates to a modified T cell, a preparation method therefor and a use thereof. The expression of endogenous TRAC, B2M and CD7 genes in the T cell is inhibited, and the T cell expresses a chimeric antigen receptor ta...
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/084519A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/085085A1 |
[Problem] To provide a method for producing a dendritic cell formulation that stimulates NKT cells, from monocytes collected from a recipient (monocytes collected by apheresis or peripheral blood containing monocytes), and that can exhib...
|
|
WO/2024/085763A1 |
The invention concerns an in vitro method for producing a 3D structure of endoderm cells, mesoderm cells and ectoderm cells and capable of further organogenesis to form an organ or organ-like cell structure. The method comprises seeding ...
|
|
WO/2024/082005A1 |
The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising the...
|
|
WO/2024/084082A1 |
The present invention relates to pluripotent stem cell comprising an expression construct for expression of a PPAR-γ protein and an expression construct for expression of a CEBPαprotein. The invention further provides for methods of...
|
|
WO/2024/085315A1 |
According to a human fibroblast culture fluid complex (G4PRF-300) effective for regenerating human tissues, a preparation method therefor, and a topical liquid composition containing same, proposed in the present invention, 26 complex gr...
|
|
WO/2024/086456A1 |
The present invention relates to a method and apparatus for passive collection of sperm having improved motility from a semen sample. The semen sample is contacted with on side of a porous barrier and a nutrient-containing media is conta...
|
|
WO/2024/083097A1 |
Disclosed in the present invention is an IL-2 mutant, having at least one of the following mutations on an amino acid sequence of IL-2: 1) an insertion of at least one amino acid residue having a smaller side chain between positions T10 ...
|
|
WO/2024/083185A1 |
The application relates to an isolated monoclonal antibody that specifically binds FGFR2B, or an antigen binding portion thereof. The application also relates to a nucleic acid molecule encoding the antibody or antigen binding portion th...
|
|
WO/2024/085251A1 |
The purpose of the present invention is to provide a method for evaluating the quality of a retinal implant without actually performing retinal implanting. The present invention relates to a method for evaluating the quality of a retin...
|
|
WO/2024/084518A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a, 100b) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop str...
|
|
WO/2024/085280A1 |
The present invention relates to a novel kynureninase and a use thereof for cancer treatment. The novel kynureninase demonstrates similar or higher catalytic activity and thermal stability compared to already known kynureninases, and is ...
|
|
WO/2024/085257A1 |
The present invention addresses the problem of providing a three-dimensional tissue culture and a method for producing the same. The problem is solved by this method for producing a three-dimensional tissue culture, the method comprising...
|
|
WO/2024/084852A1 |
The present invention relates to a nucleic acid molecule having a nucleotide sequence that encodes a chimeric antigen receptor (CAR). The present invention relates to a vector containing said nucleic acid molecule. The present invention ...
|
|
WO/2024/083021A1 |
An antibody specifically binding to TRAIL, a bispecific antibody specifically binding to TRAIL and FasL, and a pharmaceutical composition comprising the antibody specifically binding to TRAIL and an antibody and/or bispecific antibody sp...
|
|
WO/2024/086370A1 |
Provided in this disclosure is a method of cyclical production of fat cells. The method may include the steps of dedifferentiation of adipocytes into dedifferentiated fat (DFAT) cells, permitting the DFAT cells to proliferate, and re-dif...
|
|
WO/2024/086514A1 |
Disclosed are methods of creating embryonic stem cells through nuclear transfer or embryo complementation. In general, methods of complementation include contacting embryonic stem cells with a host embryo. Host embryos can be wild-type e...
|
|
WO/2024/079149A1 |
The invention relates to a method of generating a population of cardiac progenitor cells from MESP1 mesoderm cells comprising: a) incubating a MESP1 mesoderm cell in a late mesoderm induction medium comprising a WNT inhibitor for a suffi...
|
|
WO/2024/081858A1 |
Disclosed are T cell receptors (TCRs) specific for one or more neoantigens and T cells engineered to express said TCRs as well as methods of their use for treating cancer.
|
|
WO/2024/081167A1 |
The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucl...
|
|
WO/2024/079755A1 |
The present disclosure provides a method for obtaining RPE (retinal pigment epithelium) cells from iPSCs (induced pluripotent stem cells) comprising: (a) generating embryoid bodies from a culture of iPSCs, wherein the embryoid bodies are...
|
|
WO/2024/080482A1 |
The present invention relates to a composition for endometrial regeneration containing a uterus derived decellularized extracellular matrix (UdECM) and a manufacturing method therefor. Characterized by containing uterus derived decellula...
|
|
WO/2024/078643A1 |
Provided in the present invention are a genetically modified mouse cell, a mouse having a humanized immune system containing said mouse cell, and a construction method for the humanized mouse. The method comprises: inactivating a GFI1 ge...
|
|
WO/2024/077862A1 |
The use of extracellular vesicles from ginger in the preparation of a drug for promoting the proliferation of hair follicle stem cells, which use involves a method for rapidly separating extracellular vesicles from ginger. The rapid sepa...
|
|
WO/2024/077478A1 |
The present invention relates to a method for preparing extracellular vesicles having reduced non-specific binding/endocytosis. By means of performing knocking out and deglycosylating operations on extracellular vesicle-related adhesion ...
|
|
WO/2024/081884A1 |
The present disclosure provides methods and compositions for the treatment of glycogen storage diseases (e.g., GSD IX). In some aspects, the present disclosure provides splice-switching oligonucleotides that correct splicing defects and ...
|
|
WO/2024/079109A1 |
The invention relates to a genetically modified natural killer (NK) cell, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein said CAR comprises an extracellular antigen-binding domain that specifically...
|
|
WO/2024/079110A1 |
The invention relates to a nucleic acid construct for targeting and integrating a binding domain in- frame into an endogenous CD3 epsilon gene of a human cell. The invention further relates to a genetically modified human T cell comprisi...
|
|
WO/2024/080304A1 |
One embodiment of the present invention makes it possible to express, in the form of a fusion protein with a serum albumin (SA), a physiologically active protein that is expressed in a low amount and/or is less active when a host cell su...
|
|
WO/2024/078570A1 |
It relates to immune cells (e.g., T cells such as CAR-T cells, NK cells such as CAR-NK cells) modified to have no or reduced expression and/or function of one or more target proteins selected from the group consisting of: Signal Peptide ...
|
|
WO/2024/078626A1 |
Provided is a method for enhancing gene knock-in efficiency mediated by a CRISPR gene editing system in cells, comprising placing the cells in contact with a DNA-dependent protein kinase (DNA-PK) inhibitor and a cell division cyclin 7 (C...
|
|
WO/2024/081915A1 |
The present disclosure provides capture proteins for detection of antibodies specific for Kawasaki disease, methods of using the antibodies, and kits comprising the same.
|
|
WO/2024/079249A1 |
The invention relates to a hybrid AAV vector comprising a transgene of interest operably linked to an hepatocyte-specific promoter, which enhances transgene expression in the liver and its use for liver-directed gene therapy.
|
